The appealing story of HIV entry inhibitors: From discovery of biological mechanisms to drug development

Drugs

Volumn 65, Issue 7, 2005, Pages 879-904

  Castagna, Antonella ^a   Biswas, Priscilla ^a   Beretta, Alberto ^a   Lazzarin, Adriano ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETYL N [3 [4 (4 CARBAMOYLBENZYL) 1 PIPERIDINYL]PROPYL] N (3 CHLORO 4 METHYLPHENYL) 4 PIPERIDINECARBOXAMIDE; 1 BENZOYL 4 [(4,7 DIMETHOXY 1H PYRROLO[2,3 C]PYRIDIN 3 YL)OXOACETYL]PIPERAZINE; AMD 070; AMD 887; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; APLAVIROC; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DEXTRIN; DEXTRIN 2 SULFATE; ENFUVIRTIDE; GLYCOPROTEIN GP 120 INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS ENTRY INHIBITOR; INDINAVIR; KRH 2731; MARAVIROC; NEVIRAPINE; PRO 140; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; T 1249; TENOFOVIR; TIFUVIRTIDE; TNX 355; UNCLASSIFIED DRUG; VICRIVIROC; ZIDOVUDINE;

CHILL; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DRUG INHIBITION; DRUG RESISTANCE; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; GLOMERULONEPHRITIS; HEADACHE; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; META ANALYSIS; MITOCHONDRIAL TOXICITY; MULTIDRUG RESISTANCE; NAUSEA; PROTEIN INTERACTION; RASH; RECEPTOR BINDING; RESPIRATORY DISTRESS; REVIEW; RIGOR; SIDE EFFECT; SYSTEMATIC REVIEW; VIRUS ENVELOPE; VIRUS INHIBITION; VOMITING;

ANIMALS; ATTACHMENT SITES, MICROBIOLOGICAL; CD4-POSITIVE T-LYMPHOCYTES; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV-1; HUMANS; RECEPTORS, CCR5; RECEPTORS, CXCR4; VIRAL FUSION PROTEINS;

EID: 18644369147     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565070-00001     Document Type: Review

References (200)

1. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. March 23, 2004. Developed by the Panel on Clinical Practices of HIV infection convened by the Department of Health and Human Services (DHHS), USA [online]. Available from URL: http://www.hopkins-aids.edu/guidelines/ guidelines.html [Accessed 2005 Mar 17]
2. Moore JP, Doms RW. The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A 2003; 100: 10598-602
3. Marks K, Gulick RM. New antiretroviral agents for the treatment of HIV infection. Curr Infect Dis Rep 2004; 6: 333-9
4. Greene WC. The brightening future of HIV therapeutics. Nat Immunol 2004; 5: 867-71
5. Robey WG, Safai B, Oroszlan S, et al. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 1985; 228: 593-5
6. Allan JS, Coligan JE, Barin F, et al. Major glycoproteins antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 1985; 228: 1091-4
7. Chakrabarti S, Robert-Guroff M, Wong-Staal F, et al. Expression of the HTLV-III envelope gene by recombinant vaccinia virus. Nature 1986; 320: 535-8
8. Veronese FD, DeVico AL, Copeland TD, et al. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 1985; 229: 1402-5
9. Gallaher WR. Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell 1987; 50: 327-8
10. Bosch ML, Earl PL, Fargnoli K, et al. Identification of the fusion peptide of primate immunodeficiency viruses. Science 1989; 244: 694-7
11. McDougal JS, Kennedy M, Sligh J, et al. Binding of the HTLVIII/LAV to T4+ T cells by a complex of the 100 K viral protein and the T4 molecule. Science 1986; 231: 382-5
12. Kowalski M, Potz J, Basiripour L, et al. Functional regions of the human immunodeficiency virus envelope glycoprotein. Science 1987; 237: 1351-5
13. Maddon PJ, Dalgleish AC, McDougal JS, et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47: 333-48
14. Sattentau QJ, Dalgleish AG, Weiss RA, et al. Epitopes of the CD4 antigen and HIV infection. Science 1986; 234: 1120-3
15. Sattentau QJ, Weiss R. The CD4 antigen: physiological ligand and HIV receptor. Cell 1988; 52: 631-3
16. Arthos J, Deen KC, Chaikin MA, et al. Identification of the residues in human CD4 critical for the binding of HIV. Cell 1989; 57: 469-81
17. Lasky LA, Nakamura G, Smith DH, et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987; 50: 975-85
18. Bedinger P, Moriarty A, von Borstel RC, et al. Internalization of the human immunodeficiency virus does not require the cytoplasmic domain of CD4. Nature 1988; 334: 162-5
19. Lamarre D, Ashkenazi A, Fleury S, et al. The MHC-binding and the gp120-binding functions of CD4 are separable. Science 1989; 245: 743-6
20. Capon DJ, Ward RH. The CD4-gp120 interaction and AIDS pathogenesis. Annu Rev Immunol 1991; 9: 649-78
21. Smith DH, Byrn RA, Marsters SA, et al. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science 1987; 238: 1704-7
22. Deen KC, McDougal SJ, Inacker R, et al. A soluble form of CD4 (T4) protein inhibit: AIDS virus infection. Nature 1988; 331: 82-4
23. Till MA, Ghetie V, Gregory T, et al. HIV-infected cells are killed by rCD4-ricin A chain. Science 1988; 242: 1166-8
24. Rubino KL, Tarpley WG, Nicholas JA. Effects of soluble CD4 and CD4-Pseudomonas exotoxin A chimeric protein on human peripheral blood lymphocytes: lymphocyte activation and anti-HIV activity in vitro. Antiviral Res 1991; 16: 267-79
25. Traunecker A, Schneider J, Kiefer H, et al. Highly efficient neutralization of HIV with recombinant CD4-immunglobulin molecules. Nature 1989; 339: 68-70
26. Idziorek T, Chams V, Klatzmann D. Characterization and anti-HIV properties of CD4-coated red blood cells. Arch Virol 1992; 126: 81-91
27. Buonocore L, Rose JK. Prevention of HIV-1 glycoprotein transport by soluble CD4 retained in the endoplasmic reticulum. Nature 1990; 345: 625-8
28. Hart TK, Kirsh R, Ellens H, et al. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A 1991; 88: 2189-93
29. Berger EA, Lifson JD, Eiden LE. Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion. Proc Natl Acad Sci U S A 1991; 88: 8082-6
30. Thali M, Furman C, Helseth E, et al. Lack of correlation between soluble CD4-induced shedding of the human immunodeficiency virus type 1 exterior envelope glycoprotein and subsequent membrane fusion events. J Virol 1992; 66: 5516-24
31. Johnson VA, Barlow MA, Merrill DP, et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis 1990; 161: 1059-67
32. Myers MW. New antiretroviral agents in the clinic. Rev Infect Dis 1990; 12: 944-50
33. Werner A, Winskowsky G, Kurth R. Soluble CD4 enhances simian immunodeficiency virus SIVagm infection. J Virol 1990; 64: 6252-6
34. Ashorn PA, Berger EA, Moss B. Human immunodeficiency virus envelope glycoprotein CD4-mediated fusion of nonprimate cells with human cells. J Virol 1990; 64: 2149-56
35. Lores P, Boucher V, Mackay C, et al. Expression of human CD4 in transgenic mice does not confer sensitivity to human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1992; 8: 2063-71
36. McKnight A, Clapham PR, Weiss RA. HIV-2 and SIV infection of nonprimate cell lines expressing human CD4: restrictions to replication at distinct stages. Virology 1994; 201: 8-18
37. Walker CM, Erickson AL, Hsueh FC, et al. Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J Virol 1991; 65: 5921-7
38. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270: 1811-5
39. Premack BA, Schall TJ. Chemokine receptors: Gateways to inflammation and infection. Nat Med 1996; 2: 1174-8
40. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 1999; 17: 657-700
41. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272: 1955-8
42. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85: 1135-48
43. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381: 661-6
44. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381: 667-73
45. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85: 1149-58
46. Feng Y, Broder CC, Kennedy PE, et al. HIV-1 entry cofactor: cloning of a seven transmembrane G protein-coupled receptor. Science 1996; 272: 872-7
47. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1 [letter]. Nature 1998; 391: 240
48. Bleul CC, Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996; 382: 829-33
49. Oberlin E, Amara A, Bachelerie F, et al. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 1996; 382: 833-5
50. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997; 3: 1259-65
51. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185: 621-8
52. Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII: nomenclature for chemokine receptors. Pharmacol Rev 2000; 52: 145-76
53. Aramori I, Zhang J, Ferguson SG, et al. Molecular mechanism of desensitization of the chemokine receptor CCR-5: receptor signaling and internalization are dissociable from its role as an HIV-1 co-receptor. EMBO J 1997; 16: 4606-16
54. Gosling J, Monteclaro FS, Atchison RE, et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV coreceptor activity. Proc Natl Acad Sci U S A 1997; 94: 5061-6
55. Amara A, Le Gall S, Schwartz O, et al. HIV coreceptor downregulation as antiviral principle: SDF-1α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of viral replication. J Exp Med 1997; 186: 139-46
56. Alkhatib G, Locati M, Kennedy PE, et al. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. Virology 1997; 234: 340-8
57. Santoro F, Vassena L, Lusso P. Chemokine receptors as new molecular targets for antiviral therapy. New Microbiol 2004; 27 Suppl. 1: 17-29
58. Mantovani A. The chemokine system: redundancy for robust outputs. Immunol Today 1999; 20: 254-7
59. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996; 273: 1856-62
60. Huang Y, Paxton WA, Wolinsky SM, et al. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 1996; 2: 1240-3
61. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77
62. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722-5
63. Zimmerman PA, Buckler-White A, Alkhatib G, et al. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med 1997; 3: 23-36
64. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384; 179-83
65. Trkola A, Dragic T, Arthos J, et al. CD4-independent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384: 184-7
66. Rizzuto CD, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998; 280: 1949-53
67. Root MJ, Steger HK. HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 2004; 10: 1805-25
68. Weissenhorn W, Dessen A, Harrison SC, et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997; 387: 426-30
69. Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89: 263-73
70. Tan K, Liu J, Wang J, et al. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 1997; 94: 12303-8
71. Wild C, Dubay JW, Greenwell T, et al. Propensity for a leucine zipper-like domain of the human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A 1994; 91: 12676-80
72. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2: 1075-82
73. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994; 91: 9770-4
74. Lawless MK, Barney S, Guthrie KI, et al. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry 1996; 35: 13697-708
75. Judice JK, Tom JY, Huang W, et al. Inhibition of HIV type I infectivity by constrained alpha-helical peptides: implications for viral fusion mechanism. Proc Natl Acad Sci U S A 1997; 94: 13426-30
76. Furuta RA, Wild CT, Weng Y, et al. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5: 276-9
77. Callahan LN, Phelan M, Mallinson M, et al. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol 1991; 65: 1543-50
78. Batinic D, Robey FA. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem 1992; 267: 6664-71
79. Harrop HA, Coombe DR, Rider CC. Heparin specifically inhibits binding of V3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS 1994; 8: 183-92
80. Abrams DI, Kuno S, Wong R, et al. Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Ann Intern Med 1989; 110: 183-8
81. Shaunak S, Gooderham NJ, Edwards RJ, et al. Infection by HIV-1 blocked by binding of dextrin 2-sulphate to the cell surface of activated human peripheral blood mononuclear cells and cultured T-cells. Br J Pharmacol 1994; 113: 151-8
82. Javan CM, Gooderham NJ, Edwards RJ, et al. Anti-HIV type 1 activity of sulfated derivatives of dextrin against primary viral isolates of HIV type 1 in ymphocytes and monocyte-derived macrophages. AIDS Res Hum Retroviruses 1997; 13: 875-80
83. Stafford MK, Cain D, Rosenstein I, et al. A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel: a novel potential intravaginal virucide. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 213-8
84. Rosenstein IJ, Stafford MK, Kitchen VS, et al. Effect on normal vaginal flora of three intravaginal microbicidal agents potentially active against human immunodeficiency virus type 1. J Infect Dis 1998; 177: 1385-90
85. Low-Beer N, Gabe R, McCormack S, et al. Dextrin sulfate as a vaginal microbicide: randomized, double-blind, placebo-controlled trial including healthy female volunteers and their male partners. J Acquir Immune Defic Syndr 2002; 31: 391-8
86. Allaway GP, Davis-Bruno KL, Beaudry GA, et al. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11: 533-9
87. Trkola A, Pomales AB, Yuan H, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995; 69: 6609-17
88. Trkola A, Ketas T, Kewalramani VN, et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998; 72: 1876-85
89. Ketas TJ, Frank I, Klasse PJ, et al. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol 2003; 77: 2762-7
90. Hu Q, Frank I, Williams V et al. Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 2004; 199: 1065-75
91. Jacobson JM, Lowy I, Fletcher CV, et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000; 182: 326-9
92. Shearer WT, Israel RJ, Starr S, et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis 2000; 182: 1774-9
93. Prakash K, Rosenfield SI, Fisch DN, et al. Subcutaneous and intramuscular dosage forms of the HIV-1 entry inhibitor PRO 542 [abstract no. 136]. 41st Annual Meeting of the Infectious Diseases Society of America; 2003 Oct 9-12; San Diego
94. Jacobson JM, Israel RJ, Lowy I, et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 2004; 48: 423-9
95. Nagashima KA, Thompson DA, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183: 1121-5
96. Moore JP, Sattentau QJ, Klasse PJ, et al. A monoclonal antibody to CD4 domain 2 blocks soluble CD4-induced conformational changes in the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and HIV infection of CD4+ cells. J Virol 1992; 66: 4784-93
97. Reimann KA, Burkly LC, Burrus B, et al. In vivo administration to rhesus monkeys of a CD4-spedfic monoclonal antibody capable of blocking AIDS virus replication. AIDS Res Hum Retroviruses 1993; 9: 199-207
98. Reimann KA, Lin W, Bixler S, et al. A humanized form of a CD4-specific monoclonal antibody exhibits decreased antigenicity and prolonged plasma half-life in rhesus monkeys while retaining its unique biological and antiviral properties. AIDS Res Hum Retroviruses 1997; 13: 933-43
99. Reimann KA, Khunkhun R, Lin W, et al. A humanized, nondepleting anti-CD4 antibody that blocks virus entry inhibits virus replication in rhesus monkeys chronically infected with simian immunodeficiency virus. AIDS Res Hum Retroviruses 2002; 18: 747-55
100. Boon L, Holland B, Gordon W, et al. Development of anti-CD4 MAb hu5A8 for treatment of HIV-1 infection: preclinical assessment in non-human primates. Toxicology 2002; 172: 191-203
101. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189: 286-91
102. Tanox, Inc. [online]. Available from URL: http://www.tanox.com [Accessed 2005 Mar 7]
103. Lin PF, Ho H, Fan L, et al. Inhibition mechanisms of small-molecule HIV-1 attachment inhibitors [abstract no. 544]. 12th Conference on Retroviruses and Opportunistic Infections (CROI); 2005 Feb 22-25; Boston
104. Lin PF, Ho HT, Gong YF, et al. Characterization of a small molecule HIV-1 attachment inhibitor BMS-488043: virology, resistance and mechanism of action [abstract no. 535]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; Chicago
105. Hanna G, Yan JH, Fiske W, et al. Safety, tolerability, and pharmacokinetics of a novel, small-molecule HIV-1 attachment inhibitor, BMS-488043, after single and multiple oral doses in healthy subjects [abstract no. 535]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; Chicago
106. Hanna G, Lalezari J, Hellinger J, et al. Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1 infected subjects [abstract no. 141 (oral)]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; Chicago
107. Hendrix CW, Collier AC, Lederman MM, et al. Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir Immune Defic Syndr 2004; 37: 1253-62
108. Tagat JR, McCombie SW, Nazareno D, et al. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV: discovery of 1-[(4,6-dimethyl-5- pyrimidinyl)carbonyl]-4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S) -methyl-1-piperazinyl]4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem 2004; 47: 2405-8
109. Data on file, Schering-Plough Research Institute, 2004 Sep 23
110. Schurmann D, Rouzier R, Nougarede R, et al. SCH D: antiviral activity of a CCR5 receptor antagonist [abstract no. 140LB (oral)]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; Chicago
111. Dorr P, Macartney M, Rickett G, et al. UK-427,857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5 [abstract no. 12 (oral)]. 10th Conference on Retroviruses and Opportunistic Infections (CROI); 2003 Feb 10-14; Boston
112. Macartney MJ, Dorr P, Smith-Burchnell C, et al. In vitro antiviral profile of UK-427,857, a novel CCR5 antagonist [abstract no. H-875]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2003 Sep 14-17; Chicago
113. Russell D, Bakhtyari A, Jazrawi RP, et al. Multiple dose study to investigate the safety of UK-427,857 (100mg or 300mg) BID for 28 days in healthy males and females [abstract no. H-874]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2003 Sep 14-17; Chicago
114. Jenkins T, Abel S, Russell D, et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857, in healthy volunteers [abstract no. 37 (oral)]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1-3; Rome
115. Abel S, Russell D, Ridgway C, et al. The effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857, in healthy volunteers [abstract no. 41]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1-3; Rome
116. Pozniak A, Fätkenheuer G, Johnson M, et al. Effect of short-term monotherapy with UK-427,857 on viral load in HIV-infected patients [abstract no. H-443 (oral)]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2003 Sep 14-17; Chicago
117. Fätkenheuer G, Pozniak A, Johnson M, et al. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857, a novel CCR5 antagonist [abstract no. B4489]. 15th International AIDS Conference (IAC); 2004 Jul 11-16; Bangkok
118. Rosario MC, Poland W, Felstead S, et al. Modeling of UK-427,857, a novel CCR5 antagonist, efficacy in short-term monotherapy [poster; abstract no. B4479]. 15th International AIDS Conference (IAC); 2004 Jul 11-16; Bangkok
119. Data on file, Pfizer, 2004 Aug 24
120. Westby M, Smith-Burchnell C, Mori J, et al. In vitro escape of R5 primary isolates from the CCR5 antagonist, UK-427,857 is difficult and involves continued use of the CCR5 receptor [abstract no. 6 (oral)]. 13th International HIV Drug Resistance Workshop; 2004 Jun 8-12; Tenerife
121. Maeda K, Nakata H, Koh Y, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004; 78: 8654-62
122. Demarest J, Shibayama S, Ferris R, et al. A novel CCR5 antagonist, 873140, exhibits potent in vitro anti-HIV activity [abstract no. 1231 (oral)]. 15th International AIDS Conference (IAC); 2004 Jul 11-16; Bangkok
123. Nakata H, Maeda K, Kawano Y, et al. Potent in vivo anti-R5-HIV effects of AK602, a novel spirodiketopiperazine (SPD)-containing HIV-specific CCR5 inhibitor, in hu-PBMC-NOD-mice [abstract no. 564a]. 10th Conference on Retroviruses and Opportunistic Infections (CROI); 2003 Feb 10-14; Boston
124. Nakata H, Koh Y, Maeda K, et al. Greater synergistic anti-HIV effects upon combinations of CCR5 inhibitor AK602/ONO4128/GW873140 with CXCR4 inhibitors than with other anti-HIV drugs [abstract no. 543]. 12th Conference on Retroviruses and Opportunistic Infections (CROI); 2005 Feb 22-25; Boston
125. Demarest J, Adkison K, Sparks S, et al. Single and multiple dose escalation study to investigate the safety, pharmacokinetics, and receptor binding of GW873140, a novel CCR5 receptor antagonist, in healthy subjects [abstract no. 139 (oral)]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; San Francisco
126. Olson WC, Rabut GE, Nagashima KA, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999; 73: 4145-55
127. Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75: 579-88
128. Franti M, Ramos L, Maloveste S, et al. Control of HIV-1 replication in the hu-PBL-SCID mouse model by an anti-CCR5 monoclonal antibody [abstract no. 537]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; San Francisco
129. Iizawa Y, Kanzaki N, Takashima K, et al. Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonist [abstract no. 11 (oral)]. 10th Conference on Retroviruses and Opportunistic Infections (CROI); 2003 Feb 10-14; Boston
130. Schols D, Vermeire K, Hatse S, et al. In vitro anti-HIV activity profile of AMD877, a novel CCR5 antagonist, in combination with the CXCR4 inhibitor AMD070 [abstract no. 539]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; San Francisco
131. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induced stem cell mobilization by decreasing bone marrow SDF-1 and upregulating CXCR4. Nat Immunol 2002; 3: 687-94
132. Hendrix CW, Stone N, Dunaway S, et al. Biologic activity of an orally bioavailable CXCR4 antagonist in human subjects [abstract no. B4-475]. 15th International AIDS Conference (IAC); 2004 Jul 11-16; Bangkok
133. Schols D, Claes S, Hatse S, et al. Anti-HIV activity profile of AMD070, an orally bioavailable CXCR4 antagonist [abstract no. 563]. 10th Conference on Retroviruses and Opportunistic Infections (CROI); 2003 Feb 10-14; Boston
134. Murakami T, Yoshida A, Kumakura S, et al. KRH-2731-5HCl: a new potent and orally bioavailable X4 HIV-1 inhibiting CXCR4 antagonist in vivo [abstract no. LbA01 (oral)]. 15th International AIDS Conference (IAC); 2004 Jul 11-16; Bangkok
135. Murakami T, Yoshida A, Tanaka R, et al. KRH-2371: an orally bioavailable CXCR4 antagonist is a potent inhibitor of HIV-1 infection [abstract no. 541]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; Chicago
136. Matthews T, Salgo M, Greenberg M, et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004; 3: 215
137. Asboe D. Enfuvirtide: antiretroviral class 4, drug 1. HIV Clin Trials 2004; 5: 1-6
138. Fletcher CV. Enfuvirtide, a new drug for HIV infection. Lancet 2003; 361: 1577-8
139. Dando TM, Perry CM. Enfuvirtide. Drugs 2003; 63 (24): 2755-66
140. Cervia JS, Smith MA. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis 2003; 37: 1102-6
141. Robertson D. US FDA approves new class of HIV therapeutics. Nat Biotechnol 2003; 21: 470-1
142. Kliger Y, Shai Y. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J Mol Biol 2000; 295: 163-8
143. Munoz-Barroso I, Durell S, Sakaguchi K, et al. Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol 1998; 140: 315-23
144. Bray BL. Large-scale manufacture of peptide therapeutics by chemical synthesis. Nat Rev Drug Discov 2003; 2: 587-93
145. Hildinger M, Dittmar MT, Schult-Dietrich P, et al. Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 2001; 75: 3038-42
146. Reeves JD, Gallo SA, Ahmid N, et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A 2002; 99: 16249-54
147. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by corereptor specificity defined by the V3 loop of gp120. J Virol 2000; 74: 8358-67
148. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001; 75: 8605-14
149. Cilliers T, Patience T, Pillay C, et al. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses 2004; 20: 477-82
150. Poveda E, Rodes B, Toro C, et al. Are fusion inhibitors active against all HIV variants? AIDS Res Hum Retroviruses 2004; 20: 347-8
151. Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral Ther 2004; 9: 57-65
152. Su SB, Gong WH, Gao JL et al. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor. Blood 1999; 93: 3885-92
153. Hartt JK, Liang T, Sahagun-Ruiz A, et al. The HIV-1 cell entry inhibitor T-20 potently chemoattracts neutrophils by specifically activating the N-formylpeptide receptor. Biochem Biophys Res Commun 2000; 272: 699-704
154. Braun MC, Wang JM, Lahey E, et al. Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes. Blood 2001; 97: 3531-6
155. Roche. Fuzeon-enfuvirtide. Investigator's brochure. Monza: Roche S.p.A., 2003 Dec 1
156. Bonora S, Castagna A, Aguilar Marucco D, et al. Inter- and intra-individual variability of enfuvirtide (ENV) plasma trough concentrations (Ctrough) in the clinical setting [abstract no. 46]. 5th International Workshop on Clinical Pharmacology of HIV Therapy; 2004 Apr 1-3; Rome
157. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004; 18: 1958-61
158. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected ac ults. AIDS Res Hum Retroviruses 2002; 18: 685-93
159. Zhang X, Nieforth K, Lang JM, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002; 72: 10-9
160. Lalezari JP, Eron JJ, Carlson M, et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS 2003; 17: 691-8
161. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 2003; 28: 217-22
162. Bellibas SE, Siddique Z, Dorr A, et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004; 23: 1137-41
163. Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004; 44: 793-803
164. Boyd MA, Zhang X, Dorr A, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003; 43: 1382-91
165. Zhang X, Lalezari JP, Badley AD, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004; 75: 558-68
166. Kilby JM, Hopkins S, Venetta TM, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4: 1302-7
167. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003; 348: 2175-85
168. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in
169. Hasson H, Castagna A, Clementi M, et al. The introduction of fusion inhibitors in the HAART-regimens. New Microbiol 2004; 27 Suppl. 1: 11-6
170. Arasteh K, Lazzarin A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen [abstract no. B1058 (oral)]. 15th International AIDS Conference (IAC); 2004 Jul 11-16; Bangkok
171. Hornberger JC, Witek J, Kilby JM, et al. Clinical prognosis and cost-effectiveness of enfuvirtide in the United States [abstract no. H-837]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2003 Sep 14-17; Chicago
172. Church JA, Hughes M, Chen J, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004; 23: 713-8
173. Fung HB, Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 2004; 26: 352-78
174. Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy 2004; 24: 198-211
175. Cooper DA, Lange JM. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development. Lancet Infect Dis 2004; 4: 426-36
176. Cooper DA, Reiss P, Henry K, et al. The effects of enfuvirtide on body composition and serum lipids through 48 weeks in the TORO trial [poster no. 714]. 11th Conference on Retroviruses and Opportunistic Infections (CROI); 2004 Feb 8-11; Chicago
177. Cohen C, Hellinger J, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin Trials 2003; 4: 347-57
178. Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with Enfuvirtide (ENF; T-20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr 2004; 37: 1140-6
179. Walmsley S, Henry K, Katlama C, et al. Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide. J Infect Dis 2003; 188: 1827-33
180. Hasson H, Danise A, Carini E, et al. Increase in serum IgE levels during enfuvirtide treatment in multidrug-resistant HIV-1 infected patients [abstract no. B4560]. 15th International AIDS Conference (IAC); 2004 Jul 11-16; Bangkok
181. Barretina J, Blanco J, Bonjoch A, et al. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004; 18: 1673-82
182. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998; 72: 986-93
183. Zollner B, Feucht HH, Schroter M, et al. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 2001; 15: 935-6
184. Roman F, Gonzales D, Lambert C, et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003; 33: 134-9
185. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-905
186. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004; 18: 1787-94
187. Poveda E, Rodes B, Labernardiere JL, et al. Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. J Med Virol 2004; 74: 21-8
188. Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother 2004; 54: 333-40
189. Marcelin AG, Reynes J, Yerly S, et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 2004; 18: 1340-2
190. Heil ML, Decker JM, Sfakianos JN, et al. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site. J Virol 2004; 78: 7582-9
191. Menzo S, Castagna A, Monachetti A, et al. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment. Antimicrob Agents Chemother 2004; 48: 3253-9
192. Lu J, Sista P, Giguel F, et al. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004; 78: 4628-37
193. Beausejour Y, Tremblay MJ. Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane. J Infect Dis 2004; 190: 894-902
194. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004; 18: 1137-46
195. Eron JJ, Gulick RM, Bartlett JA, et al. Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV. J Infect Dis 2004; 189: 1075-83
196. Lalezari JP, Bellos NC, Sathasivan K, et al. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen. J Infect Dis 2005; 191: 1153-63
197. Martin-Carbonero L. Discontinuation of the clinical development of fusion inhibitor T-1249. AIDS Rev 2004; 6: 61
198. Roche/Trimeris conference call with investment analysts. Jan 5, 2004;
199. Trimeris: "Dear Fuzeon Investigator" Letter. Jan 5, 2004;
200. Roche Laboratories. "Following the successful development of Fuzeon, Roche and Trimeris sign new research agreement to develop next generation HIV fusion inhibitors" [press release]. 2004 Jan 6 [online]. Available from URL: http://www.trimeris.com/news/pr, 2004 [Accessed 2005 Mar 17]